IL295374A - 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders - Google Patents

3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders

Info

Publication number
IL295374A
IL295374A IL295374A IL29537422A IL295374A IL 295374 A IL295374 A IL 295374A IL 295374 A IL295374 A IL 295374A IL 29537422 A IL29537422 A IL 29537422A IL 295374 A IL295374 A IL 295374A
Authority
IL
Israel
Prior art keywords
substituted
available
hydrogen
optionally substituted
atoms
Prior art date
Application number
IL295374A
Other languages
English (en)
Hebrew (he)
Inventor
Abdelmalik Slassi
Joseph Araujo
Original Assignee
Mindset Pharma Inc
Abdelmalik Slassi
Joseph Araujo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mindset Pharma Inc, Abdelmalik Slassi, Joseph Araujo filed Critical Mindset Pharma Inc
Publication of IL295374A publication Critical patent/IL295374A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9406—Neurotransmitters
    • G01N33/942—Serotonin, i.e. 5-hydroxy-tryptamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL295374A 2020-02-04 2021-02-04 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders IL295374A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062969894P 2020-02-04 2020-02-04
PCT/CA2021/050122 WO2021155467A1 (en) 2020-02-04 2021-02-04 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders

Publications (1)

Publication Number Publication Date
IL295374A true IL295374A (en) 2022-10-01

Family

ID=77199114

Family Applications (1)

Application Number Title Priority Date Filing Date
IL295374A IL295374A (en) 2020-02-04 2021-02-04 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders

Country Status (11)

Country Link
US (3) US11453689B2 (https=)
EP (1) EP4100403A4 (https=)
JP (2) JP7824222B2 (https=)
KR (1) KR20220137085A (https=)
CN (1) CN115380028A (https=)
AU (1) AU2021215709A1 (https=)
BR (1) BR112022015379A2 (https=)
CA (1) CA3166940A1 (https=)
IL (1) IL295374A (https=)
MX (1) MX2022009528A (https=)
WO (1) WO2021155467A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
AU2022229037A1 (en) * 2021-03-02 2023-09-28 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto
BR112023024688A2 (pt) * 2021-05-26 2024-02-15 Mindset Pharma Inc Combinação de halucinógeno-ácido graxo
US20240286998A1 (en) * 2021-06-02 2024-08-29 Saint Joseph's University Fluorinated tryptamine compounds, analogues thereof, and methods using same
CA3229361A1 (en) * 2021-08-20 2023-02-23 Abdelmalik Slassi 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
EP4452939A4 (en) * 2021-12-24 2025-12-10 Kuleon Llc SEROTONINERGIC COMPOUNDS, POLYPODS, AND PROMEDICINAL PRODIGITS OF SEROTONIN RECEPTOR AGONISTS AND ANTAGONISTS
WO2023150547A2 (en) * 2022-02-01 2023-08-10 Caamtech, Inc. Psychedelic compounds and their therapeutic uses
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin
CA3248179A1 (en) * 2022-04-19 2023-10-26 Mindset Pharma Inc. Indoline derivatives used as serotonergic agents useful for the treatment of disorders associated with them
US12396981B2 (en) 2023-03-09 2025-08-26 William Shulman Methods of using DMT
WO2025104491A1 (en) 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545644A (en) 1990-10-15 1996-08-13 Pfizer Inc. Indole derivatives
US5559129A (en) 1990-10-15 1996-09-24 Pfizer Inc Indole derivatives
US5607951A (en) 1990-10-15 1997-03-04 Pfizer Inc Indole derivatives
US5120749A (en) 1991-02-20 1992-06-09 Abbott Laboratories Platelet activating antagonists
TW288010B (https=) * 1992-03-05 1996-10-11 Pfizer
US5747501A (en) * 1992-04-07 1998-05-05 Pfizer, Inc. Indole derivatives
KR960701865A (ko) * 1993-04-22 1996-03-28 데이비드 존. 우드 편두통에 사용하는 5-HT1 유사 효능제인 인돌 유도체(Indole Derivatives as 5-HT, -Like Agonists for Use in Migraine)
AP486A (en) * 1993-04-27 1996-04-16 Pfizer Indole derivatives.
FR2735774B1 (fr) 1995-06-21 1997-09-12 Sanofi Sa Utilisation de composes agonistes du recepteur cb2 humain pour la preparation de medicaments immunomodulateurs, nouveaux composes agonistes du recepteur cb2 et les compositions pharmaceutiques les contenant
CA2268399C (en) 1996-10-31 2008-08-19 Harbor Branch Oceanographic Institution, Inc. Anti-neurogenic inflammatory compounds and compositions and methods of use thereof
US6100291A (en) 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
GB9816263D0 (en) 1998-07-24 1998-09-23 Merck Sharp & Dohme Therapeutic agents
US6218423B1 (en) 1998-08-14 2001-04-17 Gpi Nil Holdings, Inc. Pyrrolidine derivatives for vision and memory disorders
GB9923314D0 (en) 1999-10-01 1999-12-08 Pfizer Ltd Acylation process
AU2001269769A1 (en) 2000-06-07 2001-12-17 The State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Methods for making bis-heterocyclic alkaloids
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
US7700612B2 (en) * 2003-12-23 2010-04-20 Abraxis Bioscience, Llc Di-ester prodrugs of camptothecin, process for their preparation and their therapeutical applications
ATE474833T1 (de) 2004-09-22 2010-08-15 Janssen Pharmaceutica Nv Inhibitoren der wechselwirkung zwischen mdm2 und p53
ZA200709038B (en) 2005-04-13 2009-01-28 Neuraxon Inc Substituted indole compounds having nos inhibitory activity
US8003624B2 (en) 2005-08-25 2011-08-23 Schering Corporation Functionally selective ALPHA2C adrenoreceptor agonists
EP1981875B1 (en) 2006-01-19 2014-04-16 Janssen Pharmaceutica N.V. Substituted indolyl-alkyl-amino-derivatives as inhibitors of histone deacetylase
US20090306137A1 (en) * 2006-05-22 2009-12-10 Wolfgang Curt D Treatment for depressive disorders
US7964728B2 (en) 2006-07-06 2011-06-21 Solvay Pharmaceuticals B.V. Azaindole derivatives with a combination of partial nicotinic acetyl-choline receptor agonism and dopamine reuptake inhibition
WO2008036967A2 (en) 2006-09-22 2008-03-27 Reddy Us Therapeutics, Inc. Novel heterocyclic compounds as lasy activators
US20090014868A1 (en) 2007-07-10 2009-01-15 International Business Machines Corporation Manufacturing ic chip in portions for later combining, and related structure
EA201000808A1 (ru) 2007-11-16 2011-04-29 Ньюраксон, Инк. Индольные соединения и способы лечения висцеральной боли
US20100022581A1 (en) 2008-07-02 2010-01-28 Memory Pharmaceuticals Corporation Pyrrolidine-substituted azaindole compounds having 5-ht6 receptor affinity
WO2010132072A1 (en) 2009-05-15 2010-11-18 Neuraxon, Inc Treatment or prevention of migraine by dosing at aura
JP5959537B2 (ja) 2011-01-28 2016-08-02 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 置換ピリジニル−ピリミジン及び医薬としてのその使用
PL3160464T3 (pl) * 2014-06-26 2018-12-31 Contera Pharma Aps 6-hydroksybuspiron do stosowania w leczeniu zaburzeń ruchowych
GB201511382D0 (en) 2015-06-29 2015-08-12 Imp Innovations Ltd Novel compounds and their use in therapy
AU2016320645B2 (en) * 2015-09-10 2019-02-28 Suven Life Sciences Limited Fluoroindole derivatives as muscarinic M1 receptor positive allosteric modulators
EP3519816A4 (en) 2016-09-29 2020-05-06 The Regents of the University of California CONNECTIONS FOR INCREASING NEURONAL PLASTICITY
WO2018094106A2 (en) 2016-11-16 2018-05-24 University Of South Florida ALLOSTERIC ANTAGONISTS OF GPRC6a AND THEIR USE IN MITIGATING PROTEINOPATHIES
EP3687514A4 (en) * 2017-09-27 2021-06-30 Ohio State Innovation Foundation METHODS AND COMPOSITIONS FOR INHIBITING STAT3
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
MA54877A (fr) 2019-01-30 2021-12-08 Diamond Therapeutics Inc Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
CA3132731A1 (en) 2019-03-07 2020-09-10 University Of Padova Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
GB201907871D0 (en) 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
CA3160793A1 (en) 2019-12-04 2021-06-10 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
BR112022015379A2 (pt) * 2020-02-04 2022-09-27 Mindset Pharma Inc Derivados de 3-pirrolidino-indol como agentes psicodélicos serotonérgicos para o tratamento de distúrbios do snc
CA3166785A1 (en) 2020-02-05 2021-08-12 Yale University Psychedelic treatment for headache disorders
US12240813B2 (en) 2020-05-19 2025-03-04 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
EP3902541B1 (en) 2020-06-02 2022-09-14 Small Pharma Ltd Therapeutic compositions comprising deuterated or partially deuterated n,n-dimethyltryptamine compounds
CN119285527A (zh) 2020-06-30 2025-01-10 瑞安神经科学公司 色胺前药
WO2022018709A1 (en) 2020-07-21 2022-01-27 Ai Pharmaceuticals Jamaica Limited Compositions and methods for treatment of psychoses and psychotic disorders
US11000534B1 (en) 2020-10-08 2021-05-11 Lennham Pharmaceuticals, Inc. Deuterated derivatives of psilocybin and uses thereof

Also Published As

Publication number Publication date
CN115380028A (zh) 2022-11-22
AU2021215709A1 (en) 2022-09-01
EP4100403A4 (en) 2024-01-03
US11453689B2 (en) 2022-09-27
JP2026053548A (ja) 2026-03-25
MX2022009528A (es) 2022-11-14
BR112022015379A2 (pt) 2022-09-27
CA3166940A1 (en) 2021-08-12
EP4100403A1 (en) 2022-12-14
JP2023512821A (ja) 2023-03-29
US12054504B2 (en) 2024-08-06
US20240336641A1 (en) 2024-10-10
US20230105399A1 (en) 2023-04-06
KR20220137085A (ko) 2022-10-11
US20220017550A1 (en) 2022-01-20
WO2021155467A1 (en) 2021-08-12
JP7824222B2 (ja) 2026-03-04

Similar Documents

Publication Publication Date Title
IL295374A (en) 3-pyrrolidine indole derivatives as serotonergic psychedelics for the treatment of central nervous system disorders
US12054505B2 (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
IL303467A (en) 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders
IL305622A (en) Indole derivatives as serotonergic agents useful in the treatment of serotonin-related disorders
US20250034106A1 (en) 3-cycloamino-indole compounds as serotonergic agents useful for the treatment of disorders related thereto
WO2024044847A1 (en) Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto
HK40083776A (en) 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40083780A (en) Psilocin derivatives as serotonergic psychedelic agents for the treatment of cns disorders
HK40105243A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物